Macquarie invites you to attend our in-person Indonesia Pharma Day in Jakarta on 19-20 September 2023.
The long-term beneficiary of the new healthcare law is Indonesian consumers, who will gain cheaper access to medical services over the longer term. We see other potential winners in the space, namely the domestic medical equipment makers, domestic drug producers and the distributors of imported medical products.
Indonesia's US$30bn healthcare industry is ripe for massive growth over the coming decade as the new law sets the foundation to industrialise the once-sleepy healthcare sector. From the hospitals that will now lead the development of new specialists to domestic pharma players that will get incentives to enable them to produce the majority of drugs and equipment domestically, the sector is poised for growth. The healthcare industry will need to embrace biotechnology, after focusing on the chemical approach for the past 30 years.
Macquarie is pleased to host our first Indonesia Pharma Day. Participants will spend the first day meeting leading companies in the sector, from drug manufacturers to medical-equipment makers. On the second day, participants will visit companies representing the whole Indonesian healthcare supply chain, from drug factories to hospitals.
DAY 1
Site visit
Etana Biotechnologies Indonesia Factory
Medikaloka Hermina (HEAL IJ) Hospital operation
Group meeting
Kalbe Farma (KLBF IJ)
DAY 2 ・Group meeting
Etana Biotechnologies Indonesia
Jayamas Medica Industri (OMED IJ)
Kimia Farma (Persero) (KAEF IJ)
Tony Ren, Macquarie Head of North Asia Healthcare Research and leads the healthcare research effort for Greater China and Japan
The long-term beneficiary of the new healthcare law is Indonesian consumers, who will gain cheaper access to medical services over the longer term. We see other potential winners in the space, namely the domestic medical equipment makers, domestic drug producers and the distributors of imported medical products.
Indonesia's US$30bn healthcare industry is ripe for massive growth over the coming decade as the new law sets the foundation to industrialise the once-sleepy healthcare sector. From the hospitals that will now lead the development of new specialists to domestic pharma players that will get incentives to enable them to produce the majority of drugs and equipment domestically, the sector is poised for growth. The healthcare industry will need to embrace biotechnology, after focusing on the chemical approach for the past 30 years.
Macquarie is pleased to host our first Indonesia Pharma Day. Participants will spend the first day meeting leading companies in the sector, from drug manufacturers to medical-equipment makers. On the second day, participants will visit companies representing the whole Indonesian healthcare supply chain, from drug factories to hospitals.
DAY 1
Site visit
Etana Biotechnologies Indonesia Factory
Medikaloka Hermina (HEAL IJ) Hospital operation
Group meeting
Kalbe Farma (KLBF IJ)
DAY 2 ・Group meeting
Etana Biotechnologies Indonesia
Jayamas Medica Industri (OMED IJ)
Kimia Farma (Persero) (KAEF IJ)
Tony Ren, Macquarie Head of North Asia Healthcare Research and leads the healthcare research effort for Greater China and Japan
